EIP Pharma announces U.S. FDA grants fast-track designation to neflamapimod as a treatment for dementia with Lewy Bodies

EIP Pharma

7 November 2019 -  EIP Pharma today announced that the Division of Neurology Products of the U.S. FDA has granted fast track designation to neflamapimod for investigation as a treatment of dementia with Lewy bodies.

Separately, EIP Pharma today announced the clinical trial results from the REVERSE-SD study of neflamapimod in early-stage Alzheimer's disease.

A Phase 2 double-blind, placebo-controlled, 16-week treatment proof-of-concept study ("AscenD-LB") of neflamapimod in mild-to-moderate DLB called is currently enrolling patients.

Read EIP Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track